Revenue Dynamics YoY (Last Twelve Months): verrica.com (VRCA)

Brandmark of verrica.com (VRCA)

Verrica Pharmaceuticals (VRCA) relies on cutting-edge dermatological developments and R&D investments. The year-over-year percentage change in sales volume for the LTM reflects market dynamics, with the indicator settling at -25.40. Patents for unique formulas and FDA approval create significant barriers to entry for competitors, while first-mover status with the drug Ycanth ensures stable business margins.

VRCA - verrica.com Sales Growth YoY (TTM) over the range 02/11/2024 - 11/19/2026

Verrica Pharmaceuticals Inc (VRCA) - metric breakdowns and financial figures

- market value and analyst target forecast:
- company stock exchange capitalization indicators:
Fundamental company valuation:Verrica Pharmaceuticals Inc.
Mass-produced product of Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals (VRCA) occupies a specialized niche in the therapy of viral dermatological diseases in the US. By analyzing the year-over-year sales trajectory over the trailing four quarters, an investor can observe the annual revenue dynamics. The -25.40 metric reflects the cash flow growth rate, excluding seasonality. This metric confirms the commercial efficiency of the unique drug delivery system. Stable growth here indicates the fundamental resilience of the business.